CSF1R and breast carcinoma: For example, LY3022855, a CSF1R blocker used as a single agent or in combination with Durvalumab (anti-PDL1 mAb) or Tremelimumab (anti-CTLA4 mAb) for patients with a solid tumors, including breast cancers (24).